Case Report

A case of losartan-induced severe hyponatremia

Saibal Das, Sanjib Bandyopadhyay¹, Anand Ramasamy², V. Vinoth Prabhu², Sudhakar Pachiappan²

Nalmuri Block Primary Health Centre, South 24 Parganas, ¹Department of Community Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, ²Department of Pharmacology, Swamy Vivekanandha College of Pharmacy, Namakkal, Tamil Nadu, India

Received: 02-11-2014 Revised: 03-01-2015 Accepted: 27-04-2015

ABSTRACT

This case report outlines a very rare case of losartan-induced severe hyponatremia in a 73-year-old type 2 diabetic patient. The patient was initiated with 50 mg daily oral losartan monotherapy for newly diagnosed moderate hypertension. After 3.5 months of taking the drug, he presented to the emergency department in a drowsy state with severe generalized weakness and occasional palpitations. He was a known diabetic for the last 3 years and well controlled by oral metformin alone. On examination, his serum sodium level was found to be 123 meq/L. There were no evidences of any other possible metabolic, infective, organic or other pathologic causes giving rise to that condition, except losartan itself. De-challenge was done and he was treated vigorously resulting in reversal of the diseased state. Naranjo adverse drug reaction probability scale suggested that it was “probable” that oral losartan was responsible for the development of severe hyponatremia in this patient.

Key words: AV block, hypertension, hyponatremia, losartan, sodium

INTRODUCTION

Angiotensin (AT₁) receptor antagonist losartan potently and selectively inhibits most of the biological effects of angiotensin II like pressor responses, vasopressin release, release of aldosterone and adrenal catecholamines, enhancement of noradrenergic neurotransmission, increases in sympathetic tone, changes in renal function, etc., It is an approved and preferred first-line drug in hypertension with a favorable safety profile. It is also widely used in diabetic nephropathy as it is supposed to be reno-protective in type 2 diabetes mellitus, by some blood pressure-independent mechanisms.[¹]

All of the physiological effects of angiotensin II, including release of aldosterone, are antagonized in the presence of losartan. Reduction in blood pressure occurs independently of the status of the renin-angiotensin system. As a result of losartan dosing, plasma renin activity increases due to removal of the angiotensin II feedback. Losartan is well absorbed following oral administration and undergoes significant first-pass metabolism to produce 5-carboxylic acid metabolite. Metabolism is primarily by cytochrome P450 isoenzymes CYP2C9 and CYP3A4.

Losartan is excreted in the urine, and in the feces via bile, as unchanged drug and metabolites.[¹]

Although teratogenic, losartan is otherwise a very safe drug. Few cases of cough and angioedema have been reported. In patients with advanced renal disease, it may cause hyperkalemia. Other rare adverse events include abnormal urticaria, hepatic dysfunction, hepatitis, agranulocytosis, neutropenia, leukopenia, Henoch-Schönleinpurpura, pruritus, hyponatremia, alopecia, and vasculitis.[¹]
CASE REPORT

A 73-year-old retired man, known diabetic and well controlled on oral metformin alone for last 3 years presented in the emergency in a drowsy state with severe generalized weakness. He reported to have nausea and occasional palpitations for the last week with occasional headache, confusion and severe lethargy in work.

Except being diabetic, he was absolutely well 3.5 months before, when he was diagnosed with asymptomatic moderate hypertension. Some routine blood tests done at that point of time are shown in Table 1. He was started with oral losartan, 50 mg daily and his blood pressure was adequately controlled within 2 weeks after taking the drug. He had no other relevant medical or surgical history. He was taking no other concomitant medications except metformin (500 mg twice daily). His bowel and bladder habits were also normal.

| Parameters detected | Values | Normal range |
|---------------------|--------|--------------|
| Hemoglobin          | 14.3 g/dL | 13.3-16.2 g/dL |
| Total WBC count     | 8700/mL | 4000-11000/mL |
| ESR                 | 9.0 mm/h | 0-15 mm/h |
| Fasting blood glucose | 109 mg/dL | 75-110 mg/dL |
| 2 h postprandial blood glucose | 132 mg/dL | 70-120 mg/dL |
| Serum urea          | 82 mg/dL | 70-120 mg/dL |
| Serum creatinine    | 0.9 ng/mL | 0.6-1.2 ng/mL |
| Serum sodium        | 141 meq/L | 136-146 meq/L |
| Serum potassium     | 4.2 meq/L | 3.5-5.0 meq/L |

**Table 2: Relevant blood and urine investigation reports after taking losartan (at the time of admission)**

| Parameters detected     | Values                        | Normal range          |
|-------------------------|-------------------------------|-----------------------|
| Total WBC count         | 8800/mL                      | 4000-11000/mL         |
| ESR                     | 9.3 mm/h                      | 0-15 mm/h             |
| Fasting blood glucose   | 104 mg/dL                    | 75-110 mg/dL          |
| 2 h postprandial blood glucose | 121 mg/dL | 70-120 mg/dL |
| Serum urea              | 84 mg/dL                     | 70-120 mg/dL          |
| Serum creatinine        | 0.9 ng/mL                    | 0.6-1.2 ng/mL         |
| Serum sodium            | 123 meq/L                    | 136-146 meq/L         |
| Serum potassium         | 3.9 meq/L                    | 3.5-5.0 meq/L         |
| Plasma osmolality       | 281 mOsmol/kg serum water    | 275-295 mOsmol/kg serum water |
| Total cholesterol       | 180.0 mg/dL                  | 200 mg/dL             |
| LDL cholesterol         | 87.0 mg/dL                   | 100 mg/dL             |
| HDL cholesterol         | 53.0 mg/dL                   | 40-60 mg/dL           |
| VLDL cholesterol        | 40.0 mg/dL                   | 6-40 mg/dL            |
| Triglyceride            | 129.7 mg/dL                  | 30-200 mg/dL          |
| Total bilirubin         | 0.9 mg/dL                    | 0.3-1.3 mg/dL         |
| Direct bilirubin        | 0.2 mg/dL                    | 0.1-0.4 mg/dL         |
| Indirect bilirubin      | 0.7 mg/dL                    | 0.2-0.9 mg/dL         |
| Serum glutamic oxaloacetate transaminase | 30.1 U/L | 12-38 U/L |
| Serum glutamic pyruvic transaminase | 23.2 U/L | 7-41 U/L |
| Alkaline phosphatase    | 88.9 IU/L                    | 20-140 IU/L           |
| Albumin                 | 4.3 g/dL                     | 4.0-5.0 g/dL          |
| Globulin                | 3.1 g/dL                     | 2.3-3.5 g/dL          |

**Table 1: Relevant blood investigation reports before initiating losartan therapy**

| Parameters detected     | Values                        | Normal range          |
|-------------------------|-------------------------------|-----------------------|
| Hemoglobin              | 14.3 g/dL                    | 13.3-16.2 g/dL        |
| Total WBC count         | 8700/mL                      | 4000-11000/mL         |
| ESR                     | 9.0 mm/h                      | 0-15 mm/h             |
| Fasting blood glucose   | 109 mg/dL                    | 75-110 mg/dL          |
| 2 h postprandial blood glucose | 132 mg/dL | 70-120 mg/dL |
| Serum urea              | 82 mg/dL                     | 70-120 mg/dL          |
| Serum creatinine        | 0.9 ng/mL                    | 0.6-1.2 ng/mL         |
| Serum sodium            | 141 meq/L                    | 136-146 meq/L         |
| Serum potassium         | 4.2 meq/L                    | 3.5-5.0 meq/L         |

WBC=White blood cells, ESR=Erythrocyte sedimentation rate, LDL=Low density lipoprotein, HDL=High density lipoprotein, VLDL=Very low density lipoprotein
On examination, the patient was in a drowsy delirious state. The pulse rate was 90/min and blood pressure was 134/88 mmHg. Except peripheral edema, no other significant findings were noted. Relevant blood and urine investigations done immediately after admission are listed in Table 2. Twelve-lead ECG showed a picture of increased PR interval. CT scan of brain revealed cerebral edema.

The patient was managed with sodium repletion, in the form of isotonic saline, coupled with dietary water restriction and promotion of water loss in excess of sodium using 40 mg i.v. twice daily frusemide for 5 days. He was discharged after 1 week in a stable condition with normalization of blood reports. He was prescribed oral hydrochlorothiazide 25 mg daily for controlling blood pressure along with 500 mg twice daily metformin as before.

**DISCUSSION**

There was no history and evidence of excessive ingotuary, gastrointestinal or renal primary loss sodium (and water) in this patient. Adrenal insufficiency (glucocorticoid deficiency), hypothyroidism, and psychogenic polydipsia were also excluded. There was no evidence of hepatic cirrhosis, heart failure or nephrotic syndrome. Chronic renal insufficiency was also ruled out from blood reports. Blood and urine osmolality, serum albumin level, liver function test and serum lipid profile were within normal limits. These features suggest that there were no other etiologies of hyponatremia in the patient except losartan. Hypoalbuminemia was also eliminated. Brain edema and increased PR interval was probably due to hyponatremia.[2,3]

Hyponatremia with losartan is a chance occurrence; it may be explained by the hypothesis that AT₁ receptor inhibition causes an angiotensin II-mediated decrease in renal tubular sodium reabsorption and reduced aldosterone release, resulting in hyperkalemia and hyponatremia.Additionally, in elderly patient with comorbid condition such as diabetes mellitus, losartan alone or in combination with a thiazide diuretic may cause such hyponatremia.[4]

A case series of patients on AT II inhibitors and thiazide diuretics presenting with hyponatremia were reported by Kim et al., Kinoshita et al. and Sharabi et al.[4-6] Although similar adverse effects were not reported earlier conclusively with losartan monotherapy, particularly in the Indian population, hyponatremia is not quite unlike with this drug.[5-9]

Naranjo adverse drug reaction probability scale[10] suggested that there was a “probable” relationship between administration of losartan and severe hyponatremia in this patient. Although a very rare finding, physicians should have high index of suspicion and rule out hyponatremia in patients taking losartan, who present with the symptoms of generalized weakness, lethargy and dizziness.

**REFERENCES**

1. Dandan RH. Renin and angiotensin. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw–Hill; 2011.p. 721-44.
2. Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. editors. Harrison's Principles of Internal Medicine. Vol 1. 17th ed. New York, NY: McGraw-Hill; 2008. p. 274-83.
3. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z. Cardiac conduction defects associated with hyponatremia. Clin Cardiol 1991;14:165-8.
4. Kim DR, Cho JH, Jang WS, Kim JS, Jeong KH, Lee TW, et al. Severe Hyponatremia associated with the use of Angiotensin II receptor blocker/thiazide combinations. Electrolyte Blood Press 2003;11:56-9.
5. Kinoshita H, Kobayashi K, Yaguramaki T, Yasuda M, Fujiki K, Tomiyama J, et al. Losartan potassium/hydrochlorothiazide (Preminent®) and hyponatremia: Case series of 40 patients. Hum Exp Toxicol 2011;30:1409-14.
6. Sharabi Y, Illan R, Kamari Y, Cohen H, Nadler M, Messerli FH, et al. Diuretic induced hyponatremia in elderly hypertensive women. J Hum Hypertens 2002;16:631-5.
7. Cozaar Side Effects Center. Available from: http://www.rxlist.com/cozaar-side-effects-drug-center.htm. [Last accessed on 2015 Jan 03].
8. Losartan potassium. Available from: http://www.drugs.com/ppa/losartan-potassium.html. [Last accessed on 2015 Jan 03].
9. Review: Could losartan potassium cause Hyponatremia (Hyponatremia)? Available from: http://www.ehealthme.com/ds/losartan+potassium+hyponatremia. [Last accessed on 2015 Jan 04].
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.